ALSO NOTED: Isis touts Phase II data; Neurocrine upbeat on trial outcome; and much more...

> Isis Pharmaceuticals reports that a mid-stage trial of ISIS 301012 produced rapid and prolonged reduction of cholesterol in patients with high cholesterol. Report

> Neurocrine Biosciences has reported positive results for a Phase II trial of NBI-56418 for endometriosis. Release

> Aradigm has gained more time and money to develop a treatment for anthrax. Report

> InterMune has launched a Phase III trial of pirfenidone, a small molecule p38-gamma inhibitor, as a treatment for patients with idiopathic pulmonary fibrosis. Release

> A week after its merger with Chiron, Novartis is laying off 111 workers in Emeryville, CA, a fraction of the employees it now has there. Report

> Doctors Without Borders has accused Abbott Laboratories of failing to fill an order for the HIV/AIDS drug Kaletra. Report

> Biotie Therapies has signed a marketing and distribution agreement with Britannia Pharmaceuticals Limited for nalmefene in the UK and Ireland. Release

And Finally… A significant minority of Pfizer's shareholders demonstrated their displeasure with the pay packages handed out to top executives, but had zero net effect on the election of 13 directors. Article

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.